Details

Project TitleCOMPARATIVE METABOLOMIC PROFILING OF THROMBOTIC MYOCARDIAL INFARCTION REVEALS A METABOLIC SIGNATURE DISTINCT FROM NON-THROMBOTIC MYOCARDIAL INFARCTION AND STABLE CORONARY ARTERY DISEASE IN HUMAN PARTICIPANTS (17005)
Track Code17005
Short Description
Abstract

COMPARATIVE METABOLOMIC PROFILING OF THROMBOTIC MYOCARDIAL INFARCTION REVEALS A METABOLIC SIGNATURE DISTINCT FROM NON-THROMBOTIC MYOCARDIAL INFARCTION AND STABLE CORONARY ARTERY DISEASE IN HUMAN PARTICIPANTS

Features and Benefits

  • A novel method of differentiating type 1 thrombotic and type 2 non-thrombotic myocardial infarction (MI).
  • When given anti-coagulants, type 2 MI patients receive no clinical benefits but still experience the higher risks of bleeding due to the medication. Differentiating between the types can eliminate this risk and lend itself to indicating

 *This Technology is available for licensing, further development, or industrial partnering*


Market Opportunities

 Currently, the state-of-the-art diagnostic tool for acute MI is measuring the concentration of troponin, a protein released when the heart muscle is damaged. This test is being performed over 50 million times per year in the USA alone, however, it can only report on dead heart muscle as opposed to the cause and therapeutic target of MI – coronary thrombosis. By testing instead for specific biomarkers related to the different subtypes of MI, diagnosis can be achieved before irreversible heart muscle cell death. Being able to distinguish between the two events gives the clinician an advantage when deciding if anti-coagulants are beneficial or harmful. These anti-coagulants are highly efficacious when applied to a coronary thrombotic event; however, when used during a non-thrombotic event, the patient receives no clinical benefit but remains subject to the associated bleeding and procedural risks.

 Further, this diagnostic test can potentially dramatically reduce the costs associated with ruling out MI by replacing the need for serial troponin measurements and stress testing, which often requires overnight hospitalization. Diagnosing non-thrombotic chest pain costs the US over $10 billion annually.

     

Technology 

This invention pertains to novel methods of differentiating between thrombotic MI and non-thrombotic MI by identifying a metabolic signature specific to the two events. By taking an arterial blood sample from enrolled patients during their coronary angiography, a metabolic profile was developed for type 1, type 2, and stable coronary artery disease (CAD) patients.

PLS-DA at time of enrollment. Analysis restricted to metabolites with significant

   

This technology can serve not only as a diagnostic tool for types 1 and 2 MI, but as a test for non-cardiac causes of symptoms consistent with cardiac etiology (chest pain, shortness of breath). This technology can also assist in targeting therapeutic agents in the prevention or treatment of both types of myocardial infarction

Technology Status

  • IP Status: Patent pending
  • Fields of Use Available: All
  • Development Status: Potential biomarkers in human participants identified

    

Researchers:

  • Andrew DeFilippis

 
TagsNone
 
Posted DateJun 22, 2017 3:26 PM